DEF 14A: Harvard Bioscience Sets Date for 2024 Annual Stockholders Meeting

Harvard Bioscience announces its 2024 Annual Meeting of Stockholders to be held virtually on May 14, 2024, to vote on director election, auditor ratification, executive compensation, and other business.

Summary

• Harvard Bioscience will hold its 2024 Annual Meeting of Stockholders virtually on May 14, 2024, at 11:00 a.m. EDT.
• Stockholders will vote on the election of one Class III Director for a three-year term expiring in 2027, the ratification of Grant Thornton LLP as the independent accounting firm for the year ending December 31, 2024, and an advisory vote on executive compensation.
• The record date for determining stockholders eligible to vote is March 20, 2024.
• The Board of Directors recommends voting FOR the election of the director nominee, FOR the ratification of the accounting firm, and FOR the advisory vote on executive compensation.
• As of the record date, there were 43,421,251 shares of Common Stock outstanding and entitled to vote at the Annual Meeting.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions. The positive aspects include the company's commitment to corporate governance and ESG matters. The negative aspects include the fact that neither Mr. Green nor Ms. Cote were eligible to receive a payment under the 2023 Annual Cash Incentive Plan.

Positives

• The Board of Directors is actively engaged in corporate governance, with regular meetings and committees overseeing key areas such as audit, compensation, and governance.
• The company has implemented a Code of Business Conduct and Ethics, demonstrating a commitment to ethical standards.
• The company is focused on environmental, social, and governance (ESG) matters, including minimizing environmental impact and fostering a fair workplace.
• The company has implemented executive stock ownership guidelines to align the interests of executives and stockholders.

Negatives

• The Compensation Committee determined that neither Mr. Green nor Ms. Cote were eligible to receive a payment under the 2023 Annual Cash Incentive Plan.

Risks

• The advisory vote on executive compensation is non-binding, meaning that the Board is not obligated to act in accordance with the outcome of the vote.
• The company faces risks related to legal, compliance, and cybersecurity matters, which are overseen by the Board of Directors.
• The company's performance-based RSUs are subject to the relative TSR of the company's Common Stock, which is subject to market fluctuations and other factors beyond the company's control.

Future Outlook

The company is focused on enabling the discovery, safety and regulatory testing, and production of tomorrows therapeutics and believes that conducting its business in a socially, environmentally, and ethically responsible manner is important to its long-term success and the well-being of its stakeholders.

Management Comments

• James W. Green, Chairman of the Board, President and Chief Executive Officer, cordially invites stockholders to attend the 2024 Annual Meeting.
• The Board of Directors recommends that you vote FOR the election of the nominee of the Board of Directors as Director of the Company; FOR the proposal to ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; and FOR the proposal to approve, by a non-binding advisory vote, of the compensation of our named executive officers.

Industry Context

This proxy statement is a standard document for publicly traded companies, providing stockholders with information necessary to make informed decisions regarding the company's governance and executive compensation. The proposals are typical for annual meetings and reflect the company's adherence to regulatory requirements and corporate governance best practices.

Comparison to Industry Standards

• The compensation peer group includes Champions Oncology, Inc., Pro-Dex, Inc., Electromed, Inc., Standard Biotools, Inc., Enzo Biochem, Inc., Suralign Holdings, Inc., IRIDEX Corporation, Surmodics, Inc., Le Maitre Vascular, Inc., T2 Biosystems, Inc., Meridian Bioscience, Inc., Transcat, Inc., OraSure Technologies, Inc., and UFP Technologies, Inc.
• These companies are similar to Harvard Bioscience based on criteria such as industry, market capitalization, revenue, and number of employees.
• The company's executive compensation practices include market comparison of executive compensation against a relevant peer group, use of an independent compensation consultant, double-trigger vesting for equity awards in the event of a change in control, limited perquisites, executive stock ownership guidelines, clawback provisions, anti-short selling, anti-margin and hedging policies, and annual say-on-pay vote.

Stakeholder Impact

• Stockholders are provided with information to make informed decisions regarding the company's governance and executive compensation.
• Employees are subject to the company's Code of Business Conduct and Ethics.
• The company's ESG initiatives may impact customers, suppliers, and communities.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on May 14, 2024.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Executive Compensation, Grant Thornton, Audit Committee, Governance, Harvard Bioscience